Prostate Cancer: The VISION Trial

Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

EP. 1: Overview of Prostate Cancer

October 19th 2021

Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.

EP. 2: Role of Imaging in Prostate Cancer

October 19th 2021

Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.

EP. 3: Treatment Options for Metastatic CRPC

October 19th 2021

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.

EP. 4: Phase 3 VISION Trial in mCRPC

October 19th 2021

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

EP. 5: Clinical Implications From the VISION Trial in mCRPC

October 19th 2021

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

EP. 6: LuPSMA Therapy in mCRPC: Managing Adverse Events

October 19th 2021

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

EP. 7: Remaining Questions for LuPSMA Therapy in mCRPC

October 19th 2021

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

EP. 8: Future Treatment Landscape of mCRPC

October 19th 2021

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

EP. 9: Clinical Pearls for the Management of mCRPC

October 19th 2021

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.